Biophan CEO to Present Drug Delivery Technologies at the Pharma Finance 2005 Conference in Rome; CEO to Outline Business and Growth Plan Through Commercialization of Intellectual Property Portfolio
"The Pharma Finance conference in Rome provides us with a valuable opportunity for high level exposure for our drug delivery technologies," said Mr. Weiner. "We are pleased to see that a number of important pharmaceutical companies are attending. We have several one-on-one meetings with these companies at the conference."
“Biophan's drug delivery technology arose from our work to fine tune nanomagnetic nanoparticles so they resonate at a specific frequency”
"Biophan's drug delivery technology arose from our work to fine tune nanomagnetic nanoparticles so they resonate at a specific frequency," Mr. Weiner explained. "The technology was originally developed in support of our work on safety and visualization of medical devices. The ability to fine tune particles to specific frequencies led to the concept of using the nanomagnetic particles to selectively control drug release as well as to reduce the toxicity of the drugs."
Details on the drug delivery technology can be viewed at http://www.biophan.com/products.php by selecting Drug Delivery from the menu.
About Pharma Finance 2005
The Pharma Finance 2005 Conference, organized by the Milano Group, is scheduled to be held June 23-24 at the Jolly Hotel - Villa Carpegna in Rome, Italy. It will bring together a range of emerging growth biotechnology companies with cutting edge, innovative research vehicles and life-enhancing product pipelines. Participating companies represent an array of therapeutic topics including oncology, cardiovascular disease, central nervous system disorders, infectious diseases and medical device technology. The event will expose companies to institutional investors, venture capitalists, senior corporate executives and experts from the scientific and medical communities. For more information, visit www.milanogroup.com.
About Biophan Technologies
Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and image compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers and interventional surgical devices such as catheters, guidewires, stents, and other implants to allow them to be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 140 U.S. patents, licenses, or applications. This total includes 38 issued U.S. patents, 9 recently-allowed applications that will issue as patents in the near future, and 93 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE:BSX) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.